Trump Administration Pushes Gun Ban for Marijuana Users
The Trump administration urged the Supreme Court to uphold a 1968 law denying gun rights to habitual users of illegal drugs, including marijuana. The case, U.S. v. Hemani, centers on Ali Hemani, a Texas man whose federal gun possession charge was dismissed by lower courts on Second Amendment grounds, though agents found a handgun and marijuana in his home during an FBI search in 2020.
Most justices expressed skepticism toward the administration’s position, with Justice Neil Gorsuch questioning why marijuana was chosen as a test case when Trump himself signed an executive order reclassifying marijuana as a lesser controlled substance. Justice Amy Coney Barrett challenged the government to provide evidence that occasional marijuana use makes someone dangerous enough to deny firearms.
Deputy Solicitor General Sarah Harris argued Congress determined mixing firearms with controlled substances is dangerous and that temporarily disarming habitual marijuana users does not violate the Second Amendment. However, Second Amendment advocate Erin Murphy countered that millions of Americans could face criminal prosecution under this interpretation, particularly since the government has not clearly proven marijuana itself is addictive and dangerous in the way Congress designated controlled substances.
The American Civil Liberties Union defended Hemani, stating that tens of millions of Americans own handguns for self-defense while also using marijuana occasionally, and the government’s broad interpretation would criminalize ordinary conduct without requiring proof of actual impairment or danger. The ACLU warned the ruling threatens to extend criminal law’s reach against lawful gun owners engaging in activities millions of Americans undertake.
The Supreme Court will decide the case by the end of June 2024, determining whether habitual marijuana use can strip individuals of Second Amendment rights despite questions from the bench about marijuana’s actual danger and the legal inconsistency created by Trump’s own drug reclassification effort.